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Interleukin 23 receptor expressing IL-17 producingT cells have been shown to be important in the development ofmurine lupus.The
usefulness of IL-23 inhibition in ameliorating lupus nephritis is unknown.We hypothesized that inhibition of IL-23 will ameliorate
nephritis in lupus-prone mice. To this end, we treated MRL/lpr lupus-prone mice for 6 weeks with a rat anti-IL-23p19 antibody,
which resulted in delaying the onset of nephritis without affecting the production of anti-dsDNA antibodies. The effect of the
treatment was hampered by the production ofmurine anti-rat IgG antibodies.The amelioration ofmurine lupus by IL-23 inhibition
strengthens the rationale for targeting IL-23 in patients with systemic lupus erythematosus.
1. Introduction
Interleukin 23 (IL-23) is a member of the IL-12 family that is
important for the generation and maintenance of Th17 cells.
Th17 cells are defined by the production of the cytokine IL-17
and play an important role not only in the defense against
microorganisms but also in autoimmune tissue damage.
Generation of Th17 cells from na¨ıve T cells depends on the
cytokine milieu, namely, the presence of IL-6, IL-1𝛽, TGF𝛽,
and IL-23. IL-23 in particular has been associated with the
generation of a particularly proinflammatory subset of Th17
that expresses both IL-17 and IFN-𝛾 [1].The importance of IL-
23 in the development of autoimmunity has been established
by the fact that IL-23 receptor knockout does not develop
experimental autoimmune encephalomyelitis (EAE) [2].
Systemic lupus erythematosus (SLE) is characterized by
deficient T regulatory capacity, increased T : B cell cooper-
ation as manifested by the production of T-cell-dependent
high affinity IgG autoantibodies, and invasion of activated T
cells into target tissues [3]. Several lines of evidence suggest
that Th17 cells may play an important role in SLE and in par-
ticular lupus nephritis; for example, SLE T cells produce IL-17
spontaneously while IL-17+ T cells are found in the kidneys
of SLE patients with nephritis. Similar to the case in patients
with SLE, IL-17 expressing T lymphocytes are abundant in the
spleen and kidneys of lupus-pronemice.Moreover, these cells
express high levels of the IL-23 receptor with its expression
increasing as the mice age and the disease progresses [4].
We have previously shown that lupus-pronemice (B6/lpr)
that are genetically deficient in the receptor for IL-23 were
protected from the massive lymphoproliferation, production
of pathogenic anti-dsDNA antibodies, and the development
of nephritis [5]. It is not known though whether blocking IL-
23 will have an effect on the ongoing inflammatory response
in lupus-prone mice. In this communication, we provide evi-
dence that indeed treatment of lupus-prone mice with anti-
IL-23 antibodies ameliorates nephritis through inhibition of
the production of IL-17 by T cells.
2. Materials and Methods
2.1. Animals. MRL/lpr/2J (MRL/lpr) were purchased from
the Jackson Laboratories (Bar Harbor, ME, USA) and housed
in the barrier animal facility of Beth Israel DeaconessMedical
Center (BIDMC). The mice were injected with anti-IL-
23p19 antibody (a gift fromBDBiosciences) intraperitoneally
three times a week. The Institutional Animal Care and Use
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Committee (IACUC) at BIDMC approved all animal-related
procedures.
Urine was collected from each group of mice that were
housed in metabolic cages overnight.The urine was analyzed
for protein, blood, and white cells using the Multistix 10 SG
reagent strips and theClinitek Status Analyzer (BayerHealth-
care). All analyses were semiquantitative according to the
manufacturer’s instructions. Albumin and creatinine in the
urine were measured using colorimetric assays according to
the manufacturer’s instructions (Albuwell M; The creatinine
companion, Exocell).
2.2. Cell Culture and Activation. Cells were isolated from
murine spleens and lymph nodes as previously described [6].
The cells were activated in vitro using a plate bound anti-CD3
(BD Biosciences) and CD28 antibody (BD Biosciences) at a
concentration of 10𝜇g/mL each. Murine IL-23 was added in
the cultures as indicated. The anti-IL-23 antibodies and the
IL-23 were added in the cell suspension immediately after the
cells were added to the precoated wells.
2.3. ELISA. IL-17 was measured by ELISA (R&D Systems);
IFN-𝛾 was measured as part of a 7-cytokine flow cytometry-
based array (Th1/Th17 cytokine bead array, BD Biosciences).
Mouse anti-rat IgG antibodies were measured using an
ELISA. Briefly, a 96-well plate was coated with rat IgG
(BD Pharmingen) overnight and, after blocking and washing
steps, was incubated with animal serum for 3 hours. Serial
dilutions of mouse anti-rat IgG (Santa Cruz) were used as
standards and goat IgG (SantaCruz) as negative control. After
several washings, the plate was incubated with goat anti-
mouse IgG HRP conjugated detection antibody (Southern
Biotech). After several washings, the HRP substrate was
added and measurements were made using an ELISA reader.
Mouse dsDNA serum levels were measured by ELISA (Alpha
Diagnostic). Mouse IgG was measured by ELISA (Immunol-
ogy Laboratories).
2.4. Statistical Analysis. The analyses were done using Graph
Pad Prism 5.0. The unpaired two-tailed 𝑡-test was used.
Statistical significance was defined as 𝑃 < 0.05.
3. Results and Discussion
We initially screened in vitro three different monoclonal
antibodies (hereby called clone A, B, and C) against IL-23 p19
subunit (BD Biosciences), which is unique for IL-23 and not
shared with the related IL-12. All three clones were developed
to bind in vitro to IL-23 but their relative biologic effectiveness
in neutralizing IL-23 was unclear. MRL/lpr splenocytes were
activated with plate-bound anti-CD3/CD28 antibodies in
vitro in the presence or absence of interleukin-23. Different
concentrations of anti-IL-23 antibodies (clones A, B, and C)
or control IgG were added in the culture as indicated in
Figure 1. The control rat IgG was used in order to control
for nonspecific effect of immunoglobulin on splenocytes.
The concentration of IL-17A was measured 24 hours later in
the supernatants. As shown in Figure 1, anti-IL-23 treatment
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Figure 1: A monoclonal anti-IL-23p19 antibody limits the IL-23-
induced production of IL-17 by MRL/lpr splenocytes. One million
MRL/lpr splenocytes were activated in vitro in the presence of
plate bound anti-CD3 and anti-CD28 antibodies (see Section 2).
IL-23 was added in the medium as indicated at a concentration of
10 ng/mL. At 24 hours later, the concentration of IL-17 wasmeasured
in the supernatants using ELISA. Asterisk (∗) signifies statistical
significance.
increased the production of IL-17 above and beyond anti-
CD3/CD28 stimulation (𝑃 = 0.03). Of all the clones and
the concentrations tested, only clone B at a concentration
of 10𝜇gr/mL was effective in blocking this IL-23-driven
production of IL-17 (P = 0.05).
Subsequently, three 9-week MRL/lpr mice were injected
with Clone B anti-IL-23p19 antibody at a dose of 20 micro-
grams per mouse three times a week intraperitoneally for
six weeks. As controls, we used three mice of the same age
and gender that were injected with the same amount of
an unrelated monoclonal rat IgG antibody. At the initiation
of the treatment, no mouse had an active urine sediment.
Nevertheless, themice had detectable anti-dsDNAantibodies
in their serum suggesting that immunologic tolerance was
already broken. As can be seen in Figure 2(a), only control
treated mice developed pyuria. Similarly, the anti-IL-23
treated mice developed proteinuria at a lower level and at a
later time-point than control treated mice (Figure 2(b)). Yet,
at the end of the treatment, the size of spleens and number
of cells in the spleen and lymph nodes were not different
between the two groups. The levels of ds-DNA antibodies
(Figure 2(c)) were similar between the groups. Moreover,
total serum IgG was comparable between the two groups
(control versus anti-IL-23 treated IgG (ng/mL): 576.6 ± 167.5
versus 702.1 ± 164.5, P = 0.4). These results suggested that
this treatment had minimal effect on humoral immunity.
Histologic examination of the kidneys at the end of the
treatment disclosed no differences between the two groups.
Mice from both groups had histologic findings of significant
glomerulonephritis with cell proliferation, deposition of IgG
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Figure 2: SixMRL/lprmicewere treated for the indicated timewith 20 𝜇g of anti-IL-23p19 antibody given intraperitoneally three timesweekly
or control rat IgG. Urine was collected weekly. (a) The presence of leucocytes was assessed using a semiquantitative method. (b) Albumin
and creatinine were measured using a colorimetric technique and the ratio is presented here. (c) dsDNA antibody levels were measured in
the serum using a sandwich ELISA.
and C3 in the glomerulus, and cell infiltration in the inter-
stitium (data not shown). Additionally, none of the animals
developed skin lesions during this trial.
At the end of the treatment, splenocytes were harvested
and assayed in vitro for the production of cytokines. We
found that splenocytes from the anti-IL-23 treated mice
produced less IL-17A than control mice when stimulated in
vitro (Figure 3(a)).There were no differences though between
the two groups in the production of IFN-𝛾, IL-2, IL-6, and
TNF-𝛼 (data not shown). These findings suggested that the
anti-IL-23 treatment specifically decreased the production of
IL-17 without significantly affectingTh1 cytokine production.
Given the fact that the injected antibody was rat anti-
murine IL-23, we examinedwhether themice developed anti-
rat IgG antibodies. Indeed, we found that mostly the treated
mice and less so the control mice developed murine anti-rat
IgG (Figure 3(b)). Of note, the level of anti-rat antibodies did
not correlate with the level of dsDNA antibodies in the serum
of individual mice (data not shown). The presence of these
antibodies may have negatively impacted the effect of anti-
IL-23 treatment in these mice.
In this proof of concept study, we show for the first time
that targeting IL-23 with a monoclonal antibody ameliorates
nephritis in lupus-prone mice. This treatment was associated
with a decrease in IL-17 production and no significant
changes in Th1 activity, further emphasizing the pivotal role
that IL-17 producing T cells are playing in lupus nephritis.
Another important finding was that the anti-IL-23 treat-
ment was effective despite the fact that the treated mice had
already established humoral autoimmunity at the beginning
of the treatment. Moreover, production of total IgG and
dsDNAautoantibodies by the treatedmice did not differ from
that of controls at the end of the study, suggesting that (a)
the effect of this treatment was mediated primarily by its
effect on T cells and (b) cellular responses are important in
the pathogenesis of lupus nephritis independent of immune
complexes/anti-dsDNA antibodies. It has to be pointed out
though that the lack of significant decrease in anti-dsDNA
4 BioMed Research International
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Figure 3: (a) At the end of the treatment, theMRL/lprmice were sacrificed and the splenocytes were stimulated in vitrowith anti-CD3/CD28
antibodies for 24 hours. IL-17A was measured in the supernatant by ELISA. (b) Serum levels of anti-rat IgG were measured by sandwich
ELISA as described in Section 2.
antibody levels in the treated group may also be responsible
for the modest effect of this treatment.
Besides the ineffectiveness of this antibody in decreasing
anti-dsDNA levels, it also caused the production of anti-rat
IgG antibodies at very high levels; this was also observed in
mice treated with control rat antibody albeit at much lower
levels. Human anti-drug antibodies have been well known to
decrease the efficacy and cause infusion reactions of biologics
such as anti-TNF antibodies used for rheumatoid arthritis
[7]. Based on this well-known effect of biologics, we postulate
that the development of mouse anti-rat antibodies may have
significantly limited the effect of the anti-IL-23p19 antibody
in abrogating nephritis. Future studies will be needed to fully
characterize the usefulness of anti-IL-23 treatment in lupus,
usingmurine anti-mouse antibodies thatwill not sensitize the
mice and lead to inadvertent production of these anti-drug
antibodies.
As mentioned above, we were not able to assess the role
of IL-23 in the development of autoreactive B cells, as the
mice already had high levels of anti-dsDNA at the start of
the treatment. Our previous studies showed that anti-dsDNA
levels were almost undetectable in lupus-prone mice that are
IL-23 receptor deficient [5]. Contrary to that, elimination of
IL-17 did not result in dsDNA level decrease in the Fc𝛾RIIb-
deficient lupus-pronemouse [8]. Differences in the target (IL-
23 versus IL-17), the mouse model, and the approach (genetic
deletion versus inhibition) may account for these differences.
Therefore, further studies will be needed to address the
effect of IL-23 and Th17 cells in the development of humoral
autoimmunity in lupus-prone mice.
In conclusion, these findings in lupus-prone mice call for
further investigation of the role of IL-23 in SLE. As biologics
targeting IL-23 become available [9], the precise effect of this
cytokine in the generation, maintenance of autoimmunity,
and the ensuing inflammatory damage of targetorgans will
need to be elucidated in order to design novel therapeutic
regimens for the treatment of SLE.
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